BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is a rare, non-Hodgkin lymphoma that remains incurable. Rituximab, an anti-CD20 monoclonal antibody has been the cornerstone of treatment against WM, and its combination with an alkylator, bendamustine, achieves durable remission in treatment-naive patients with sy...
में बचाया:
| मुख्य लेखकों: | , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
MDPI AG
2023-04-01
|
| श्रृंखला: | Hemato |
| विषय: | |
| ऑनलाइन पहुंच: | https://www.mdpi.com/2673-6357/4/2/12 |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|